Handelsavisen
prelaunch
Companies Healthcare 074430.KQ
07
074430.KQ KOSDAQ Pharmaceuticals

074430.Kq

$1 225,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
11,5 %
ROE
6,3 %
Net margin
16,0 %
Debt / equity
0,29
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
6,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 074430.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 074430.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 26,455,983,070, which represents a significant portion of its total assets of KRW 84,178,004,620. The liquidity FPT (free cash flow to total liabilities) is robust, indicating the company's ability to meet short-term obligations without external financing. The current ratio of 2.85 further supports this, showing that the company has more than enough current assets to cover its current liabilities.

    Profitability metrics indicate a solid performance, with a return on equity (ROE) of 6.29% and a return on assets (ROA) of 4.18%. These figures are in line with the industry's preferred metrics, suggesting the company is effectively utilizing its equity and assets to generate returns. The operating income of KRW 2,535,847,270 and net income of KRW 3,521,555,420 reflect a healthy margin structure, which is a positive sign for long-term sustainability.

    The company's revenue is not segmented by geographic regions or product lines in the provided data, so it is not possible to assess revenue concentration or geographic exposure. However, the absence of disclosed segments does not necessarily indicate a lack of diversification; it may reflect the company's reporting practices or the nature of its operations.

    The company's growth trajectory is supported by a positive free cash flow of KRW 3,965,349,420 and a capital expenditure of KRW -45,700,000, indicating that it is generating more cash than it is spending on capital investments. This suggests a focus on maintaining and optimizing existing operations rather than aggressive expansion. The outlook for the current fiscal year and the next fiscal year is not explicitly provided, but the company's financial health supports a stable growth path.

    Risk factors for the company are currently assessed as low in terms of liquidity and dilution. The debt-to-equity ratio of 0.29 indicates a conservative capital structure, with a relatively low proportion of debt compared to equity. There are no immediate filing-based liquidity or dilution flags, and the dilution potential is low, suggesting that the company is not expected to issue additional shares in the near term to raise capital.

    There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The company appears to be operating in a stable environment with no immediate threats to its financial health. The absence of recent events does not imply a lack of activity but may reflect the timing of the data collection or the nature of the company's operations.

    Key takeaways
    • The company has a strong liquidity position, supported by high cash reserves and a favorable current ratio.
    • Profitability metrics are in line with industry standards, indicating effective use of assets and equity.
    • The company's capital structure is conservative, with a low debt-to-equity ratio and no immediate dilution risks.
    • Free cash flow is positive, suggesting the company is generating more cash than it is spending on capital investments.
    • There are no immediate filing-based liquidity or dilution flags, indicating a stable financial position.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1 225,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $55.99B
    Net cash
    $10.24B
    Current ratio
    2.9
    Debt / equity
    0.3
    ROA
    4.2%
    ROE
    6.3%
    Cash conversion
    72.0%
    CapEx / revenue
    -0.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin11,5 %Above median
    Net Margin16,0 %Above P75
    ROE6,3 %Above median
    Capex / Rev-0,2 %Above P75
    D/E0,29Below median
    Cash Conv0,72Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 074430.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    074430.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage